SNY Relative Valuation - Sanofi SA

Watchlist Manager

Watchlist

Price: 44.77 USD 0.38% Market Closed

Market Cap: $111.8B

	Sanofi SA NASDAQ:SNY	FR
	Zinc of Ireland NL ASX:ZMI	AU

Relative Value

The Relative Value of one SNY stock under the Base Case scenario is 79.32 USD. Compared to the current market price of 44.77 USD, Sanofi SA is Undervalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

SNY Relative Value

Base Case

Undervaluation 44%

Relative Value

Price

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
FR		Sanofi SA NASDAQ:SNY	92.9B USD	2	11.9	10	10
US		Eli Lilly and Co NYSE:LLY	860.3B USD	13.2	41.7	28.1	30
US		Johnson & Johnson NYSE:JNJ	566.9B USD	6	21.1	14.7	18.1
CH		Roche Holding AG SIX:ROG	243.3B CHF	3.9	18.6	11.1	12.5
UK		AstraZeneca PLC LSE:AZN	215.5B GBP	4.9	28	15.6	21.9
US		Merck & Co Inc NYSE:MRK	286.3B USD	4.4	15.7	9.7	11.9
CH		Novartis AG SIX:NOVN	221.8B CHF	5.1	20.6	12.8	16.4
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1.1T DKK	3.4	10.3	7.6	8.9
US		Pfizer Inc NYSE:PFE	152.2B USD	2.4	19.6	7.6	10.1
US		Bristol-Myers Squibb Co NYSE:BMY	114.7B USD	2.4	16.3	6.9	8.5

				Revenue Growth	P/S to Growth
FR		Sanofi SA NASDAQ:SNY	Average P/S: 13.6 2	5%	0.4
US		Eli Lilly and Co NYSE:LLY	13.2	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6	6%	1
CH		Roche Holding AG SIX:ROG	3.9	4%	1
UK		AstraZeneca PLC LSE:AZN	4.9	7%	0.7
US		Merck & Co Inc NYSE:MRK	4.4	5%	0.9
CH		Novartis AG SIX:NOVN	5.1	5%	1
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.4	2%	1.7
US		Pfizer Inc NYSE:PFE	2.4	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
FR		Sanofi SA NASDAQ:SNY	Average P/E: 20.4 11.9	16%	0.7
US		Eli Lilly and Co NYSE:LLY	41.7	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.1	7%	3
CH		Roche Holding AG SIX:ROG	18.6	14%	1.3
UK		AstraZeneca PLC LSE:AZN	28	26%	1.1
US		Merck & Co Inc NYSE:MRK	15.7	14%	1.1
CH		Novartis AG SIX:NOVN	20.6	14%	1.5
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.3	1%	10.3
US		Pfizer Inc NYSE:PFE	19.6	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.3	16%	1

				EBITDA Growth	EV/EBITDA to Growth
FR		Sanofi SA NASDAQ:SNY	Average EV/EBITDA: 45.4 10	19%	0.5
US		Eli Lilly and Co NYSE:LLY	28.1	22%	1.3
US		Johnson & Johnson NYSE:JNJ	14.7	2%	7.4
CH		Roche Holding AG SIX:ROG	11.1	6%	1.8
UK		AstraZeneca PLC LSE:AZN	15.6	13%	1.2
US		Merck & Co Inc NYSE:MRK	9.7	3%	3.2
CH		Novartis AG SIX:NOVN	12.8	5%	2.6
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.6	1%	7.6
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	6.9	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
FR		Sanofi SA NASDAQ:SNY	Average EV/EBIT: 99.1 10	12%	0.8
US		Eli Lilly and Co NYSE:LLY	30	22%	1.4
US		Johnson & Johnson NYSE:JNJ	18.1	6%	3
CH		Roche Holding AG SIX:ROG	12.5	6%	2.1
UK		AstraZeneca PLC LSE:AZN	21.9	21%	1
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
CH		Novartis AG SIX:NOVN	16.4	9%	1.8
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.9	2%	4.5
US		Pfizer Inc NYSE:PFE	10.1	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.5	-7%	N/A

Sanofi SA
NASDAQ:SNY

Relative Value

Valuation Multiples

Multiples Across Competitors

SNY Competitors Multiples
Sanofi SA Competitors

See Also

Company

Help

Tools

Stocks

Sanofi SA NASDAQ:SNY

Relative Value

Valuation Multiples

Multiples Across Competitors

SNY Competitors Multiples Sanofi SA Competitors

See Also

Company

Help

Tools

Stocks

Sanofi SA
NASDAQ:SNY

SNY Competitors Multiples
Sanofi SA Competitors